Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Sustained effect of seralutinib on circulating biomarkers in the TORREY phase 2 open-label extension study

Friday, January 31, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The TORREY phase 2 open-label extension study demonstrates that seralutinib has a sustained effect on circulating biomarkers. This finding suggests that seralutinib may offer continued benefits for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The results could enhance treatment strategies in these areas.
Price reaction · baseline $0.9637 (2025-01-30 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows sustained effects on circulating biomarkers.
  • The study indicates promising results for patients.
  • Potential for improved treatment options in PAH and PH-ILD.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Sustained effect of seralutinib on circulating biomarkers in the TORREY phase 2 open-label extension study
PVRI – January 2025c
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib?

Seralutinib is a medication being studied for its effects on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What does the TORREY study focus on?

The TORREY study focuses on the sustained effects of seralutinib on circulating biomarkers in patients.

What are the implications of the study results?

The study results suggest that seralutinib may provide ongoing benefits for patients with PAH and PH-ILD.

Is the study open-label?

Yes, the TORREY study is an open-label extension study.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib phase 2 PAH PH-ILD biomarkers
Last updated: Jan 31, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →